(Hypertension. 1996;27:1090-1096.)
© 1996 American Heart Association, Inc.
Articles |
From the Medical Research Council of Canada (MRC) Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal (Quebec, Canada).
| Abstract |
|---|
|
|
|---|
Key Words: cardiomyocytes calcium, intracellular angiotensin II receptor, angiotensin
| Introduction |
|---|
|
|
|---|
Ang IImediated effects occur via specific membrane receptors. Two Ang II receptor subtypes (AT1 and AT2) have been identified by ligand binding studies with nonpeptide Ang II antagonists.12 AT1-R is blocked by DuP 753 (losartan), and AT2-R is blocked by PD 123177 and CGP 42112A.12 AT1-R has been cloned, and its second messenger system includes phospholipase C activation, Ca2+ mobilization, and protein kinase C stimulation,12 13 whereas the functional role of AT2-R remains obscure.12 Two subvariants of the AT1-R, AT1A and AT1B, have been identified in the rat through DNA sequencing.14 These subvariants exhibit small differences (5%) in amino acid sequence but otherwise give identical binding results with Ang II analogues, and both utilize the Ca2+ pathway as a cytosolic second messenger.15 In the rat heart, Ang II receptor expression is increased during the neonatal period and decreases with maturation.16 The proportions of AT1-R and AT2-R are similar in the rat myocardium and do not change through development.17 18 The heart contains two major cell types: cardiomyocytes and fibroblasts.19 Although high-affinity Ang II binding sites have been demonstrated in cardiac tissues,17 which cardiac cell type is responsible for the binding sites is unclear. Some studies have demonstrated that fibroblasts express AT1-R rather than AT2-R,20 whereas others have reported that isolated adult and neonatal rat cardiomyocytes exclusively exhibit AT1-R.8 21 It has also been suggested that the Ang II receptor is expressed primarily in fibroblasts and not in cardiomyocytes.22 Thus, the receptor distribution in isolated cardiac cells appears distinct from that in cardiac tissue.
We designed this study to evaluate the effects of Ang II on [Ca2+]i transients in primary cultured neonatal atrial and ventricular cardiomyocytes and to determine which Ang II receptor subtype mediates these responses. We demonstrate for the first time that responses to Ang II differ in atrial and ventricular neonatal cardiomyocytes and that these differential responses may be due to the presence of AT1A-R and AT1B-R in atrial cells but only AT1A-R in ventricular cells.
| Methods |
|---|
|
|
|---|
After incubation, the cells were dispersed by pipetting, and the remaining tissue was digested for another 20 minutes in 15 mL collagenase-DNAse solution. The dispersed cells were suspended in fetal calf serum, filtered through a nylon mesh, centrifuged, and resuspended in complete serum-free medium (CSFM-1) plus 10% Nu-Serum IV (Collaborative Research Inc). They were counted in a hematocytometer, diluted, and seeded in plastic six-well multidishes that contained round glass coverslips (25 mm diameter, Fisher Scientific Inc) at a density of 1.25x105 cells per centimeter squared. The plated cells were grown on the glass coverslips at 37°C in 5% CO2/95% air. Unlike the method described by Shields and Glembotski24 in which plated cells were maintained for the first 24 hours in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, we maintained cells in CSFM-125 with 10% Nu-Serum IV. The day after seeding, the medium was replaced with CSFM-2 supplemented with cytosine arabinofuronoside, which was removed from the medium after 3 days. All studies were performed 5 days after isolation when the cells were contracting spontaneously and synchronously.
Measurement of Cardiomyocyte
[Ca2+]i
The cells attached to the glass coverslips were washed three
times with warmed (37°C) modified Hanks' buffered saline solution
containing (mmol/L) NaCl 137, NaHCO3 4.2,
Na2HPO4 3, KCl 5.4,
KH2PO4 0.4, CaCl2 1.3,
MgCl2 0.5, MgSO4 0.8, glucose 10, and HEPES 5
(pH 7.4). The washed cells were loaded with fura 2AM (4 µmol/L)
that was dissolved in dimethyl sulfoxide with 0.02% pluronic F-127 and
incubated at 37°C for 30 minutes in a humidified incubator (5%
CO2/95% air). The loaded cells were then washed
with the modified Hanks' buffer. Four glass rings (diameter, 4 to 5
mm) were placed on the coverslip containing cells, and a vacuum seal
was formed between the ring and the coverslip with vacuum grease (Dow
Corning Co). Each ring was filled with 50 µL modified Hanks' buffer.
This method physically isolated four areas on the glass coverslip and
allowed for four separate experiments per coverslip. Two methods were
used for measurement of [Ca2+]i: in isolated
cells by microphotometry and in cell clusters by fluorescent
digital imaging. The advantage of microphotometric measurements is that
the frequency of data point collection is faster than that for digital
imaging. The advantages of digital imaging are that multiple individual
cells can be examined simultaneously and that the cells
under investigation can be imaged throughout the experiment. Although
the systems were calibrated by different methods, microphotometric
[Ca2+]i results obtained in basal and
stimulated cells were comparable to those obtained from digital imaging
analysis.
For microphotometric determinations, the coverslip containing cells and rings was placed in a Leiden chamber (Medical System Corp) on top of the stage of an inverted microscope equipped for epifluorescence with a x40 oil-immersion objective (Diaphot TMD, Nikon). Fluorescence measurements of single cells were made microphotometrically according to previously described methods.26 [Ca2+]i was calculated according to the formula of Grynkiewicz et al.27 In addition, [Ca2+]i was measured in multiple cells (8 to 16 cells per experiment) simultaneously by fluorescent digital imaging with the Axiovert 135 inverted microscope and Attofluor Digital Fluorescence System (Zeiss) using excitatory wavelengths of 343 and 380 nm. This system was calibrated by viewing fura 2 solutions containing zero and saturating calcium concentrations and including these data in the ratio calculations for construction of a standard curve relating calcium concentration to the 343/380 ratio. For [Ca2+]i measurement by imaging microscopy, the chamber containing the glass coverslip with adherent cells was mounted on the stage of the Axiovert inverted microscope, which was equipped for fluorescence measurements. Video images of fluorescence at 520 nm emission were obtained by an intensified CCD camera system (Zeiss) with the output digitized to a resolution of 512x480 pixels. The Attofluor hardware and software are capable of digitizing and displaying the video at the RS170 video rate of 4 to 30 frames per second. Images of fluorescence ratios were then obtained by dividing, pixel by pixel, the 343-nm image after background subtraction by the 380-nm image after background subtraction. With prior in vitro calibration, the Attofluor system allowed for direct intracellular free calcium measurement, which was graphed and analyzed by the AttoGraph for Windows program (Zeiss).
[Ca2+]i effects of various Ang II concentrations (10-11 to 10-5 mol/L) were determined. Cells were used for single experiments and exposed to one peptide concentration only. This was achieved by addition of 50 µL of the appropriate Ang II concentration to the 50 µL of buffer contained within the glass ring that isolated the cells under investigation. The maximum peak ratio recorded was considered as the maximal response of the agonist. Responses occurred within 15 seconds after the agonist had been introduced.
Cardiomyocyte Membrane Preparations
Methods for preparation of membranes of cultured
cardiomyocytes were based on previously described
techniques.23 In brief, atria and ventricles were
homogenized in 0.05 mol/L NaHCO3, pH
7.4, and 0.1 mmol/L phenylmethylsulfonyl fluoride (PMSF) with a
polytron (Brinkmann Instruments) (two times for 10 seconds) and
centrifuged at 3000g for 10 minutes. Atrial and
ventricular membranes were prepared separately. The pellet
was rehomogenized, and both supernatants were pooled
and centrifuged at 40 000g for 15 minutes. The
pellet was washed in 0.05 mol/L Tris-HCl, pH 7.4,
recentrifuged at the same speed, and resuspended in the
same buffer.
Cultured cardiomyocytes in 10-cm plastic dishes were washed twice with 0.02 mol/L NaHCO3, pH 7.4, and 0.1 mmol/L PMSF and scraped in the same buffer (1 mL/60 cm2). The cells were homogenized in a Potter-Elvehjem homogenizer at 750 rpm with 10 strokes and centrifuged at 40 000g for 15 minutes. The pellet was resuspended in 0.05 mol/L Tris-HCl, pH 7.4. All membrane preparations were kept at -40°C until used.
Ang II Binding Assay
Ang II receptor subtypes were assessed by
radioligand binding studies.
[Sar1,Ile8]Ang II was radiolabeled by
the lactoperoxidase method.28 The specific activity of
labeled [Sar1,Ile8]Ang II (1500
Ci/mmol) was assessed by self-displacement.29 For
competition analysis,23 membrane proteins (30 to
50 µg) were incubated with 50 000 cpm of
125I-[Sar1,Ile8]Ang II in
the presence of increasing concentrations
(10-13 to
10-6 mol/L) of peptide, losartan,
or PD 123319. After 60 minutes of incubation at room temperature, the
volume was aspirated and filtered on a No. 34 glass filter (Schleicher
& Schuell) with a cell harvester (Brandel). The filters were presoaked
and washed with 0.05 mol/L Tris, pH 7.2, and 0.15 mol/L NaCl.
Radioactivity on the filters was counted in a gamma counter (LKB,
Wallac). Data were analyzed by the EBDA and LIGAND software of
McPherson30 (Biosoft).
RT-PCR of AT1A-R and AT1B-R and Southern
Blot Analysis
Total RNA was extracted from frozen cell pellets of atrial and
ventricular cardiomyocytes and from fresh
frozen aorta and mesenteric artery tissue from Sprague-Dawley
rats by the guanidinium isothiocyanate/phenol/chloroform extraction
method.31 The RNA samples were resuspended in
diethylpyrocarbonate-treated H2O, and the optical
density was determined at 260 and 280 nm. First strand cDNA was
synthesized with 5 µg total RNA in a 50-µL reaction mixture
containing (mmol/L) Tris-HCl 50 (pH 8.3), KCl 50, MgCl2 10,
dithiothreitol 10, dNTPs 1, and spermidine 0.5 as well as 1 µg oligo
NOT 1-dT18 primer (Pharmacia) and 10 U/µg RNA avian
myeloblastosis virus reverse transcriptase (Promega) for 1 hour at
42°C. The tubes were boiled, and bovine pancreas ribonuclease
(Pharmacia) was added to a final concentration of 1 µg/mL. Five
microliters of first strand cDNA was used for PCR amplification in a
50-µL reaction mixture containing (mmol/L) Tris-HCl 10 (pH 8.3),
MgCl2 1.5, and KCl 50 as well as 0.1% Triton X-100, 200
µmol/L dNTPs, 100 pmol of each primer, and 2 U Taq DNA
polymerase (Promega). PCR amplification was performed in an Easy Cycler
(Ericomp, Inc) programmed as follows: 5 minutes initial denaturation at
95°C, 30 cycles each including 1 minute denaturation at 95°C, 1
minute annealing at 55°C, and 1 minute elongation at 72°C followed
by a final elongation for 10 minutes at 72°C. A 351-bp
AT1A-Rspecific PCR product was obtained with the
forward primer 5'-GCAGCCTCTGACTAAATG-3' and the reverse primer
5'-AGTTGAACAGAACAAGTG-3' located at nucleotides 1398 to
1416 and 1730 to 1748, respectively, of the 3' untranslated
region.32 33 A 427-bp AT1B-Rspecific PCR
product was obtained with the forward primer
5'-CCATTTGGGCTAAGCAGC-3' and the reverse primer
5'-CAATGGTGTCATAGTCAC-3', located at nucleotides 1716 to
1734 and 2124 to 2142, respectively, of the 3' untranslated
region.14 34 As a control for the RT analysis of
RNA samples and genomic DNA contamination, a ß-actin PCR
amplification was performed simultaneously. A 234-bp PCR
product was obtained with the forward primer
5'-AGACCTCTATGCCAACACACT-3' and the reverse primer
5'-ATGGAGGGGCGGACTCATC-3' located within exons D and E, respectively,
of the ß-actin gene.35 Contamination of total RNA
extracts with genomic DNA would result in a ß-actin PCR
product of 357 bp because of a 125-bp spacing intron. After PCR, a
15-µL sample of the amplified products was separated by
electrophoresis on a 1% agarose gel. The DNA was denatured and
transferred to a nylon membrane (Hybond-N, Amersham) by capillary
action according to the manufacturer's instructions. The membrane was
dried and the DNA fixed by UV irradiation with a UV Stratalinker
(Stratagene). The membrane was prehybridized for 3 hours at room
temperature in 50 mmol/L phosphate buffer (pH 7.0) containing 5x SSC
(20x SSC: 3 mol/L NaCl, 0.3 mol/L sodium citrate), 1% sodium
dodecyl sulfate, 100 µg/mL yeast tRNA, 5x Denhardt's
solution (50x Denhardt's solution: 1% Ficoll, 1%
polyvinylpyrrolidone, 1% bovine serum albumin), 50%
formamide, and 100 µg/mL sonicated salmon sperm DNA. An antisense
oligonucleotide common to both amplified
AT1-R fragments (5'-TGTTCCTTTTGATTTCCAC-3';
underlined base is an A in AT1B cDNA) was used as a probe
for verification of the identity of the AT1A and
AT1B amplified products. The
oligonucleotide was labeled with T4
polynucleotide kinase (Pharmacia) and
[
-32P]ATP (3000 Ci/mmol, Amersham). The
32P-labeled oligonucleotide was purified by
chromatography with an NACS cartridge (Gibco-BRL).
Hybridization was carried out with 5x106 cpm (10 mL
total) of the 32P-labeled probe for 18 to 20 hours at room
temperature. The membranes were washed three times for 20 minutes at
room temperature in 6x SSC, dried with paper towels, wrapped in
plastic wrap, and exposed to Reflection film (DuPont) with intensifying
screens at -70°C for 6 hours.
Statistical Analysis
For each experiment, at least four measurements were made by
microphotometry and at least six by fluorescent digital
imaging. Data obtained from digital imaging studies in which multiple
cells were examined in each experiment were calculated as mean
[Ca2+]i per experiment and then as the mean
of multiple experiments. Since results in isolated single cells
(measured microphotometrically) and in cell clusters (measured by
digital imaging) were similar, data obtained by the two systems were
pooled, and the mean [Ca2+]i value was
determined.
Data are presented as mean±SE. Comparison of mean values was performed by ANOVA or Student's t test as appropriate. Concentration-response curves were fitted by nonlinear regression, and the concentration giving 50% of the maximal response (EC50) was determined and pD2 calculated as -log [EC50 (mol/L)].
| Results |
|---|
|
|
|---|
Basal [Ca2+]i in Neonatal
Cardiomyocytes
[Ca2+]i measurements are
presented as diastolic, systolic, and mean
values according to previously described definitions.8
Diastolic [Ca2+]i was determined
as the average of the lowest point of each tracing over a 30-second
interval (Fig 1
). The systolic value was taken
as the average of the maximal points corresponding to the
diastolic [Ca2+]i (Fig 1
). The
mean value was calculated as the midpoint between the systolic
and diastolic values, and the
[Ca2+]i amplitude was taken as the difference
between systolic and diastolic values (Fig 1
). The
frequency of cell beating corresponded to the frequency of
[Ca2+]i spikes and was determined over 1
minute. Diastolic [Ca2+]i was
62±2.4 nmol/L in atrial cells and 60±2.1 nmol/L in
ventricular cells. The corresponding systolic
[Ca2+]i values were 135±2.1 and 123±1.9
nmol/L in atrial and ventricular cells, respectively. The
mean [Ca2+]i values
([systolic+diastolic]/2) were 99±1.3 nmol/L
(atrial cells) and 90±1.1 nmol (ventricular cells). The
[Ca2+]i transient amplitudes were 73±4
nmol/L (atrial cells) and 63±2 nmol/L (ventricular cells).
The frequencies of [Ca2+]i spikes were
26±0.5 beats per minute (atrial cells) and 20±2 beats per minute
(ventricular cells).
|
Effects of Ang II on Ca2+ in Neonatal
Cardiomyocytes
Ang II increased [Ca2+]i responses in a
dose-dependent manner (Fig 2
). The pD2
values were 8.2±0.22 (atrial cells) and 8.0±0.22
(ventricular cells). In subsequent experiments, Ang II was
used at a fixed concentration of 10-9
mol/L because this is a low pharmacological dose corresponding to an
EC30 that elicits significant
[Ca2+]i responses. Ang II
(10-9 mol/L) significantly increased
[Ca2+]i responses in cells derived from the
atrium and ventricle. Mean [Ca2+]i values
were significantly increased (P<.01) to 249±5 nmol/L
(atrial cells) and 229±6 nmol/L (ventricular cells) (Fig 1
). Ang II significantly increased (P<.01)
[Ca2+]i amplitude (164±8 nmol/L, atrial
cells; 102±4 nmol/L, ventricular cells) as well as the
frequency of [Ca2+]i spikes (38±1 beats per
minute, atrial cells; 34±0.8 beats per minute, ventricular
cells). Ang IIinduced mean [Ca2+]i and
[Ca2+]i amplitude were significantly greater
(P<.05) in atrial compared with ventricular
cells (Fig 1
). Time-course analysis demonstrated that
within 100 seconds after Ang II addition,
[Ca2+]i responses returned to baseline values
(Fig 3
).
|
|
Effects of [Sar1,Ile8]Ang II,
Losartan, and PD 123319 on Ang IIStimulated
[Ca2+]i Transients in Neonatal
Cardiomyocytes
Exposure of cells to 10-7 mol/L
[Sar1,Ile8]Ang II, a specific Ang II
receptor blocker, abolished the Ang IIinduced
[Ca2+]i effects. When cells were preexposed
to 10-7 mol/L losartan, a
specific AT1-R blocker, responses to
10-9 mol/L Ang II were significantly
blocked (Fig 1
). Preincubation with PD 123319
(10-5 to
10-8 mol/L), an AT2
antagonist, failed to block the Ang IIinduced
[Ca2+]i effects.
Ang II Receptor Binding Studies
Competition binding curves indicated the presence of a single
population of high-affinity binding sites for Ang II in
ventricular and atrial cells. The apparent dissociation
constant for atrial cells (Kd) was 0.71±0.11
µmol/L and Bmax was 54±3.4 fmol/mg protein
(n=3), which was similar to that for ventricular cells.
Losartan caused complete displacement of
125I-[Sar1,Ile8]Ang II,
whereas PD 123319 had no effect (Fig 4
).
|
RT-PCR Analysis of AT1A-R and
AT1B-R Expression
We performed RT-PCR analysis to determine whether the
AT1A-R and AT1B-R genes are expressed in rat
neonatal cardiomyocytes. Fig 5
(top) shows a
PCR amplification product of 351 bp specific for the
AT1A-R in both atrial (lanes 1 and 3) and
ventricular (lane 5) rat neonatal cardiomyocyte
preparations. The amplification product of 427 bp specific for the
AT1B-R subtype was only evident in atrial cells (lanes 2
and 4) and in repeated experiments (n=7 from different cell
preparations) was absent from ventricular neonatal
cardiomyocytes (lanes 6, 8, 9, and 10). Southern blot
analysis of the amplified products with the use of specific
32P-labeled oligonucleotide probes
independent of the PCR primers (Fig 5
, bottom) confirmed that the PCR
bands were consistent with the AT1A-R and
AT1B-R sequences. As positive controls, we also performed
RT-PCR analysis in rat aortic and mesenteric vascular tissue.
AT1A-R and AT1B-R mRNAs were expressed in both
aorta and mesenteric vessels (data not shown). PCR amplification of
ß-actin indicates the efficiency of the cDNA synthesis by RT of
RNA samples obtained from the cardiomyocytes. Furthermore,
the presence of a single 234-bp ß-actin PCR amplification
product from these preparations and absence of a 357-bp
ß-actin PCR amplification product that would have been
present if genomic DNA had been amplified indicates that the
AT1-R PCR amplification products from atrial and
ventricular cardiomyocytes were derived
specifically from reverse transcribed mRNA transcripts and were not due
to amplification of genomic DNA.
|
| Discussion |
|---|
|
|
|---|
Basal [Ca2+]i was similar in cells derived from the atrium and ventricle, but [Ca2+]i responsiveness to Ang II was significantly greater in atrial cells. To the best of our knowledge, no other studies have compared Ang IIinduced [Ca2+]i responses between atrial and ventricular cells. The implications of these differential effects may be related to the functional variability of the atrium and ventricle. Increased Ang IIevoked [Ca2+]i transients in atria may contribute to the active atrial conducting system, whereas the lower Ang IIinduced [Ca2+]i responses in ventricles may be associated with cardiac contraction. These proposals await elucidation. A possible underlying mechanism for the different [Ca2+]i responses between atrial and ventricular cells may be the differences in expression patterns of AT1-R subvariants, specifically the presence of AT1A-R and AT1B-R in neonatal atrial cardiomyocytes and of AT1A-R only in neonatal ventricular cardiomyocytes.
[Sar1,Ile8]Ang II, a specific Ang II receptor antagonist, abolished the [Ca2+]i effects of Ang II, demonstrating that the responses were receptor mediated. The selective AT1-R antagonist losartan completely blocked the Ang IImediated increase in [Ca2+]i, whereas PD 123319, the AT2-R antagonist, even at high concentrations, had no effect. Thus, Ang IIinduced [Ca2+]i responses in neonatal atrial and ventricular cardiomyocytes are mediated via the AT1-R subtype. Binding studies confirmed these findings and demonstrated a single population of high-affinity binding sites for Ang II. These results are consistent with data from preparations in other species as well as from the rat.38 39 We have also demonstrated for the first time that the AT1A-R and AT1B-R genes are expressed in neonatal rat atrial cardiomyocytes, whereas only the AT1A-R gene is expressed in ventricular cells. [Ca2+]i responsiveness to Ang II was greater in atrial compared with ventricular cells, and this may be related to differential AT1-R subtype distribution in atrial and ventricular cells. Other studies have also demonstrated both subtypes of the AT1-R in cardiac tissue, but none have examined atrial and ventricular cardiomyocytes separately. Matsubara et al16 recently reported that in neonatal rat cardiomyocytes (combined atrial and ventricular cells), the AT1B-R mRNA level was 1.5-fold higher than the AT1A-R mRNA level, whereas Iwai et al15 showed that in adult rat ventricular cells, the proportion of AT1A mRNA to AT1B mRNA was 1 to 2. It may be possible that AT1A-R and AT1B-R expressions are developmentally regulated and that with cardiac maturation, cell and subtype distribution change.
In conclusion, this study demonstrates that Ang II increases the amplitude and frequency of [Ca2+]i transients in neonatal rat cardiomyocytes via Ang II receptors of the AT1-R subtype. [Ca2+]i responsiveness to Ang II was greater in atrial compared with ventricular cells, and this could be related to the expression of AT1A-R and AT1B-R subvariants in neonatal atrial cardiomyocytes but only of the AT1A subvariant in neonatal ventricular cardiomyocytes.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
| Footnotes |
|---|
Received June 16, 1995; first decision September 19, 1995; accepted January 10, 1996.
| References |
|---|
|
|
|---|
2.
Schomisch MC, Schluchter MD, Parandal L.
Inotropic effects of angiotensin II on human cardiac muscle
in vitro. Circulation. 1990;82:1973-1984.
3. Ishihata A, Endoh M. Pharmacological characteristics of the positive inotropic effect of angiotensin II in the rabbit ventricular myocardium. Br J Pharmacol. 1993;108:999-1005. [Medline] [Order article via Infotrieve]
4.
Blumberg AL, Ackerly JA, Peach MJ.
Differentiation of neurogenic and myocardial angiotensin II
receptors in isolated rabbit atria. Circ
Res. 1975;38:26-30.
5.
Morgan HE, Baker KM. Cardiac
hypertrophy: mechanical, neural and endocrine
dependence. Circulation. 1991;83:13-25.
6. Dostal DE, Baker KM. Evidence for a role of an intracardiac renin-angiotensin system in normal and failing hearts. Trends Cardiovasc Med. 1993;3:67-74.
7.
Allen IS, Cohen NM, Dhallan RS, Gaa ST, Lederer WJ,
Rogers TB. Angiotensin II increases spontaneous
contractile frequency and stimulates calcium current in cultured
neonatal rat heart myocytes: insights into underlying biochemical
mechanisms. Circ Res. 1988;62:524-534.
8.
Kem DC, Johnson EIM, Capponi AM, Chardonnens D, Lang
U, Blondel B, Koshida H, Vallotton MB. Effect of
angiotensin II on cytosolic free calcium in neonatal rat
cardiomyocytes. Am J Physiol. 1991;261:C77-C85.
9.
Baker KM, Singer HA, Aceto JF.
Angiotensin II receptor mediated stimulation of cytosolic
free calcium and inositol phosphates in chick myocytes.
J Pharmacol Exp Ther. 1989;251:578-585.
10.
Abdellatif MM, Neubauer CF, Lederer WJ, Rogers
TB. Angiotensin-induced desensitization of the
phosphoinositide pathway in cardiac cells occurs at the
level of the receptor. Circ Res. 1991;69:800-809.
11.
Capogrossi MC, Kaku T, Filburn CR, Pelta DJ, Hansford
RG, Spurgeon HA, Lakkata EG. Phorbol ester and
dioctanoylglycerol stimulate membrane association of protein kinase C
and have a negative inotropic effect mediated by changes in cytosolic
Ca2+ in adult rat cardiac myocytes.
Circ Res. 1990;66:1143-1155.
12. Timmermans PBMWM, Wong PC, Chiu AT. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45:205-251. [Medline] [Order article via Infotrieve]
13. Smith RD, Chiu AT, Wong PC, Herblin WF, Timmermans PBMWM. Pharmacology of nonpeptide angiotensin II receptor antagonists. Annu Rev Pharmacol Toxicol. 1992;32:135-165. [Medline] [Order article via Infotrieve]
14. Iwai N, Inagami T. Identification of two subtypes in the rat type I angiotensin II receptor. FEBS Lett. 1992;298:257-260. [Medline] [Order article via Infotrieve]
15. Iwai N, Inagami T, Ohmichi N, Nakamura Y, Saeki Y, Kinoshita M. Differential regulation of rat AT1a and AT1b receptor mRNA. Biochem Biophys Res Commun. 1992;188:298-303. [Medline] [Order article via Infotrieve]
16. Matsubara H, Kanasaki M, Murasawa S, Tsukaguchi Y, Nio Y, Inada M. Differential gene expression and regulation of angiotensin II receptor subtypes in rat cardiac fibroblasts and cardiomyocytes in culture. J Clin Invest. 1994;93:1592-1601.
17.
Suzuki J, Matsubara H, Urakami M, Inada M. Rat
angiotensin II (type A) in myocardial growth and
hypertrophy. Circ Res. 1993;73:439-447.
18.
Sechi LA, Griffin CA, Grady EF, Kalinyak JE, Schambelan
M. Characterization of angiotensin II receptor
subtypes in rat heart. Circ Res. 1992;71:1482-1489.
19. Pinson A, Padieu P, Harary I. Techniques for culturing heart cells. In: Pinson A, ed. The Heart Cell in Culture. Boca Raton, Fla: CRC Press; 1987;1:7-22.
20.
Schorbb W, Booz GW, Dostal DE, Conrad KM, Chang KC,
Baker KM. Angiotensin II is mitogenic in
neonatal rat cardiac fibroblasts. Circ
Res. 1993;72:1245-1254.
21.
Meggs LG, Coupet J, Huang H, Cheng W, Li P, Capasso JM,
Homcy CJ, Anversa P. Regulation of angiotensin II
receptors on ventricular myocytes after myocardial
infarction in rats. Circ Res. 1993;72:1149-1162.
22. Iwami K, Do YS, Hsueh WA. Intracardiac distribution of angiotensin II AT1 receptors. Hypertension. 1993;22:419. Abstract.
23.
Thibault G, Doubell AF, Garcia R, Larivière R,
Schiffrin EL. Endothelin-stimulated secretion of
natriuretic peptides by rat atrial myocytes is mediated by
endothelin A receptors. Circ Res. 1994;74:460-470.
24.
Shields PP, Glembotski CC. The
post-translational processing of rat pro-atrial
natriuretic factor by primary atrial myocyte
cultures. J Biol Chem. 1988;263:8091-8098.
25. Glembotski CC, Gibson TR. Molecular forms of immunoactive atrial natriuretic peptide released from cultured rat atrial myocytes. Biochem Biophys Res Commun. 1985;132:1008-1017. [Medline] [Order article via Infotrieve]
26. Touyz RM, Tolloczko B, Schiffrin EL. Mesenteric vascular smooth muscle cells from SHR display increased Ca2+ responses to angiotensin II but not to endothelin-1. J Hypertens. 1994;12:663-673. [Medline] [Order article via Infotrieve]
27. Grynkiewicz G, Poenie M, Tsien TY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;160:3440-3450.
28. Murthy KK, Thibault G, Schiffrin EL, Garcia R, Chartier L, Gutkowska J, Genest J, Cantin M. Disappearance of atrial natriuretic factor from circulation in the rat. Peptides. 1986;7:241-246.
29. Morris BJ. Specific radioactivity of radioimmunoassay tracer determined by self-displacement: a reevaluation. Clin Chim Acta. 1976;73:213-216. [Medline] [Order article via Infotrieve]
30. McPherson GA. Analysis of radioligand binding experiments: a collection of computer programmes for the IBM PC. J Pharmacol Methods. 1985;14:213-228. [Medline] [Order article via Infotrieve]
31. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159. [Medline] [Order article via Infotrieve]
32. Iwai N, Yamano Y, Chaki S, Konishi F, Bardhan S, Tibbetts C, Sasaki K, Hasegawa M, Matsuda Y, Inagami T. Rat angiotensin II receptor: cDNA sequence and regulation of the gene expression. Biochem Biophys Res Commun. 1991;177:299-304. [Medline] [Order article via Infotrieve]
33. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature. 1991;351:233-236. [Medline] [Order article via Infotrieve]
34. Guo DF, Inagami T. The genomic organisation of the rat angiotensin II receptor AT1b. Biochim Biophys Acta. 1994;1218:91-94. [Medline] [Order article via Infotrieve]
35.
Nudel U, Zakut R, Shani M, Neuman S, Levy Z, Yaffe
D. The nucleotide sequence of the rat cytoplasmic
beta-actin gene. Nucleic Acids Res. 1983;11:1759-1771.
36.
Kohmoto O, Ikenouchi H, Hirata Y, Momomura S-I,
Serizawa T, Barry WH. Variable effects of
angiotensin II on cytosolic free calcium in neonatal rat
cardiomyocytes. Am J Physiol. 1993;265:H793-H800.
37.
Leatherman GF, Kim D, Smith TW. Effect of
phorbol esters on contractile state and calcium flux in chick heart
cells. Am J Physiol. 1987;253:H205-H209.
38.
Rogers TB, Gaa ST, Allen IS. Identification and
characterization of functional angiotensin II receptors on
cultured heart myocytes. J Pharmacol Exp
Ther. 1986;236:438-444.
39.
Lokuta AJ, Cooper C, Gaa ST, Wang HE, Rogers TB.
Angiotensin II stimulates the release of
phospholipid-derived second messengers through multiple receptor
subtypes in heart cells. J Biol Chem. 1994;269:4832-4838.
This article has been cited by other articles:
![]() |
R. Laszlo, C. Eick, N. Rueb, S. Weretka, H.-J. Weig, J. Schreieck, and R. F Bosch Inhibition of the renin-angiotensin system: effects on tachycardia-induced early electrical remodelling in rabbit atrium Journal of Renin-Angiotensin-Aldosterone System, September 1, 2008; 9(3): 125 - 132. [Abstract] [PDF] |
||||
![]() |
C.-T. Tsai, L.-P. Lai, K.-T. Kuo, J.-J. Hwang, C.-S. Hsieh, K.-L. Hsu, C.-D. Tseng, Y.-Z. Tseng, F.-T. Chiang, and J.-L. Lin Angiotensin II Activates Signal Transducer and Activators of Transcription 3 via Rac1 in Atrial Myocytes and Fibroblasts: Implication for the Therapeutic Effect of Statin in Atrial Structural Remodeling Circulation, January 22, 2008; 117(3): 344 - 355. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-C. Ueng, T.-P. Tsai, W.-C. Yu, C.-F. Tsai, M.-C. Lin, K.-C. Chan, C.-Y. Chen, D.-J. Wu, C.-S. Lin, and S.-A. Chen Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation: Results of a prospective and controlled study Eur. Heart J., December 1, 2003; 24(23): 2090 - 2098. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Liu, D. A. Misurski, and V. Gopalakrishnan Cysteinyl leukotriene-dependent [Ca2+]i responses to angiotensin II in cardiomyocytes Am J Physiol Heart Circ Physiol, April 1, 2003; 284(4): H1269 - H1276. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-S. Zhao, T. D. Gallardo, L. Lin, J. J. Schageman, and R. V. Shohet Transcriptional mapping and genomic analysis of the cardiac atria and ventricles Physiol Genomics, December 26, 2002; 12(1): 53 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. G. Daniels, R. S. Keller, and P. P. de Tombe Losartan prevents contractile dysfunction in rat myocardium after left ventricular myocardial infarction Am J Physiol Heart Circ Physiol, November 1, 2001; 281(5): H2150 - H2158. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ravassa, M. A. Fortuno, A. Gonzalez, B. Lopez, G. Zalba, A. Fortuno, and J. Diez Mechanisms of Increased Susceptibility to Angiotensin II-Induced Apoptosis in Ventricular Cardiomyocytes of Spontaneously Hypertensive Rats Hypertension, December 1, 2000; 36(6): 1065 - 1071. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Nakashima, K. Kumagai, H. Urata, N. Gondo, M. Ideishi, and K. Arakawa Angiotensin II Antagonist Prevents Electrical Remodeling in Atrial Fibrillation Circulation, June 6, 2000; 101(22): 2612 - 2617. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Methot, M. C. LaPointe, R. M. Touyz, X.-P. Yang, O. A. Carretero, C. F. Deschepper, E. L. Schiffrin, G. Thibault, and T. L. Reudelhuber Tissue Targeting of Angiotensin Peptides J. Biol. Chem., May 16, 1997; 272(20): 12994 - 12999. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Touyz, J. Fareh, G. Thibault, and E. L. Schiffrin Intracellular Ca2+ Modulation by Angiotensin II and Endothelin-1 in Cardiomyocytes and Fibroblasts From Hypertrophied Hearts of Spontaneously Hypertensive Rats Hypertension, November 1, 1996; 28(5): 797 - 805. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1996 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |